Navigation Links
Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
Date:4/11/2013

ements, among others, relating to our future capital requirements and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and unc
'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
2. Pharmacyclics, Inc. Prices Public Offering of Common Stock
3. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
4. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
5. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
6. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
7. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
8. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
9. New survey finds women who suffer from migraines want a better understanding of migraine triggers
10. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
11. Cardinal Health Foundation, The Ohio State University Launch Fourth Toolkit to Help Reduce Abuse of Prescription Drugs on College Campuses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Calif. , Nov. 20, 2014  Edwards Lifesciences ... in the science of heart valves and hemodynamic monitoring, ... giving in 2014 to support a strong launch of ... Matters , and to improve the global communities where ... 2014, Edwards, global corporate giving will exceed $8 million, ...
(Date:11/21/2014)... , Nov. 20, 2014 /CNW Telbec/ - KLOX Technologies ... the following appointments: Todd Martensen ... the newly created role of Chief Commercial Officer, to ... using topical photoconverter gel for the treatment of chronic ... traumatic wounds, recently approved in Europe ...
(Date:11/21/2014)... Fla. , Nov. 20, 2014   Coqui ... become the first U.S. commercial producer of Molybdenum-99 (Mo-99), ... contract with INVAP to design its Medical ... Mo-99 is the parent isotope of Technetium-99, ... procedures worldwide. In 2012, Congress passed legislation making it ...
Breaking Medicine Technology:Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... 2010 United Seating & Mobility (USM) , one ... excited to announce today that it has finalized a transaction ... The transaction applies to Fridley, MN serving the greater ... and Appleton, WI; RehabTECH will continue to operate its Illinois ...
... Dec, 2, 2010 SRI International, an independent ... it is collaborating with PhenoMatriX (PMX), a biotechnology ... drugs such as cisplatin and related analogues are ... have served as major weapons against solid tumors ...
Cached Medicine Technology:SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies 2SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies 3SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies 4
(Date:11/22/2014)... Greenville, Sc (PRWEB) November 23, 2014 ... officially opened its doors in the downtown Greenville area. ... of Downtown Greenville , decided to open her own ... such amazing results with the patients. , AlignLife ... the proper tools. With a focus on chiropractic care ...
(Date:11/22/2014)... 2014 PrettyTailor , an outstanding ... new big promotion. Customers can buy new dresses at ... can visit its website. , As a matter of ... dresses. It mainly provides four types of wedding outfits, ... flower girl dresses. It also provides a variety of ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 A classic black ... of the most famous dress suppliers, has unveiled its new ... new dresses are now offered at a big discount, up ... special offer. , The new black prom dresses, made ... order to meet the needs of all customers, the company ...
(Date:11/22/2014)... 2014 BambooFlooringChina.com is a famous ... proudly released its new collection of bamboo mats ; ... to 29% off. , According to the sales ... grass, making it a highly renewable resource. Their bamboo mats ... mixing color which comes from natural bamboo with caramel bamboo ...
(Date:11/22/2014)... New York, NY (PRWEB) November 22, 2014 ... Australia’s Therapeutics Goods Administration (TGA) approved it for ... Glutathione was approved and listed within the Therapeutic ... http://www.comlaw.gov.au/Details/F2014L01277 , Kyowa Hakko’s Setria® Glutathione ... Chem, a biotech specialist that sources and imports ...
Breaking Medicine News(10 mins):Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2Health News:New Black Prom Dresses from BellasDress.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3
... Childhood cancer survivors diagnosed later with non-melanoma skin cancer ... tumor within 15 years, according to research led by ... percent of survivors in this Childhood Cancer Survivor Study ... skin cancer developed another more aggressive cancer within 15 ...
... June 2010 Elsevier, a world-leading healthcare and ... an agreement with Tarrytown, New York based InfoDesk ... for pharmaceutical and life science companies. The ... technological know-how paves the way for the development ...
... available in German . Early detection is ... every lump turns out to be a malignant tumor. To ... a biopsy and examine the removed tissue under the microscope. ... but also highly time consuming. Research scientists at the Fraunhofer ...
... 8, 2010) A University of Minnesota study definitively shows ... an increased life expectancy. The research is published in the ... The findings stem from the Program on Surgical Control ... at the University of Minnesota in 1975. Researchers evaluated 838 ...
... unique study with sunitinib suggest that it might be ... to treat HIV-positive cancer patients to achieve therapeutic benefit. ... treat their HIV, much more or considerably less chemotherapy ... NCI-supported AIDS Malignancy Consortium (AMC). The trial design ...
... 2010 The Institute for Research in Immunology and ... a new research funding model that brings together the ... accelerate the discovery of new anti-cancer therapeutics. Inspired by ... athletes at the Vancouver Winter Olympics, B2Discovery,s mission is ...
Cached Medicine News:Health News:Non-melanoma skin cancer may help identify survivors at increased risk for future cancers 2Health News:Elsevier and InfoDesk collaborate to co-develop federated drug pipeline intelligence solution 2Health News:Detecting tumors faster 2Health News:Consortium seeks best treatment for HIV-positive cancer patients 2Health News:Consortium seeks best treatment for HIV-positive cancer patients 3Health News:B2Discovery: Entrepreneurs and researchers join forces to conquer cancer 2
... Activins are polypeptide hormones which belong ... superfamily. The TGF- superfamily is a ... which control many aspects of development, ... Other members incude TGF-s, bone morphogenetic ...
... also known as bone Gla protein, is ... is a major component of the noncollagenous ... osteoblasts in bone, with a small amount ... chondrocytes [1]. During bone formation, newly synthesized ...
... Insulin-like growth factor binding protein-2 (IGFBP-2) is ... have been proposed) which specifically bind and ... The binding affinity of IGFBP-2 for IGF-II ... for IGF-I [1], suggesting a role in ...
... suppress the secretion of FSH (follicle stimulating ... two distinct chains, or subunits (alpha and ... the alpha-subunit and betaA-subunit. Inhibin B consists ... dimeric forms of the molecule, containing both ...
Medicine Products: